



LAW OFFICES
MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
ARLINGTON COURTHOUSE PLAZA I
SUITE 1400
2200 CLARENDON BOULEVARD
ARLINGTON, VIRGINIA 22201
TELEPHONE: (703) 243-6333
CABLE: USALAW INT'L TELEX: 64191
TELECOPIER: (703) 243-6410

RECEIVED

JAN 24 2001

TECH CENTER 1600/2800

In re application of: Jan ENDRIKAT et al.
Serial No.: 09/091,665
Filed: September 2, 1999

Atty's Docket No. SCH 1637

THE ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231

Sir:

Transmitted herewith is an amendment in the above-identified application.

I hereby certify that this correspondence is being deposited
with the U.S. Postal Services as First Class Mail in an envelope
addressed to: Assistant Commissioner of Patents and Trademarks,
Washington, D.C. 20231 On: 1/16/01
Name: Nancy Axelrod
Signature: Nancy Axelrod
Date: 1/16/01

- ☐ Small entity status of this application under 37 C.F.R. §1.9 and §1.27 has been established by a verified statement previously submitted. ☐ Verified statement(s) to establish small entity status under 37 C.F.R. §1.9 and §1.27 enclosed.
- ☐ No additional fee is required.

The fee has been calculated as shown below.

(1)	(2) CLAIMS REMAINING AFTER AMENDMENT	(3)	(4) HIGHEST NO. PREVIOUSLY PAID FOR	(5) PRESENT EXTRA	(6) RATE	(7) ADDITIONAL FEE
TOTAL CLAIMS	* 35	MINUS	** 30	5	x \$18.00	\$90.00
INDEP. CLAIMS	* 8	MINUS	*** 6	2	x \$80.00	\$160.00
<input type="checkbox"/> FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM						
				TOTAL ADDITIONAL FEE FOR THIS AMENDMENT		\$250.00

- * If entry in Col. 2 is less than entry in Col. 4, write "0" in Col. 5.
** If "Highest No. Previously Paid For" in this space is less than 20, write "20" in this space.
*** If "Highest No. Previously Paid For" in this space is less than 3, write "3" in this space.

The "Highest No. Previously paid For" (total or independent) is the highest number found from the equivalent box in col. 2 of a prior amendment or the number of claims originally filed.

- ☒ The amount of \$ 250.00 is included in the attached check.
- ☐ Please charge my Deposit Account No. 13-3402 in the amount of \$ _____. Two copies of this sheet are attached for this purpose.
- ☒ A separate Request for Extension of Time is attached.
- ☒ The Commissioner is hereby authorized to charge any deficiencies in payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 13-3402.
- ☒ Any filing fees under 37 C.F.R. §1.16 for the presentation of extra claims.
- ☒ Any patent application processing fees under 37 C.F.R. §1.17.

Respectfully submitted,

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.

DATE: January 16, 2001 (Monday)

BY: Brion P. Heaney (Reg. No. 32,542)

Nancy J. Axelrod
Nancy J. Axelrod (44,014)
Patent Agent


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Jan ENDRIKAT et al.

Serial No.: 09/091,665

Filed: September 2, 1998



Group Art Unit: 1616

Examiner: Qazi, S.

#13/C
JEP
1/31/01
RECEIVED

JAN 24 2001

TECH CENTER 1000-230

For: CONTRACEPTIVE PROCESS AND KIT FOR FEMALE MAMMALS,
COMPRISING A COMBINATION OF GESTAGEN AND OESTROGEN

REPLY

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

I hereby certify that this correspondence is being deposited
with the U.S. Postal Services as First Class Mail in an envelope
addressed To: Assistant Commissioner of Patents and Trademarks,
Washington, D.C. 20231 On: 1/16/01
Name: Nancy Axelrod
Signature: Nancy Axelrod
Date: 1/16/01

This Reply is responsive to the Office Action dated August 15, 2000.

IN THE CLAIMS

Please add new claims 31-35 as follows.

--31. A contraceptive combination which contains at least 28 daily dosage units with
(a) a first phase that consists of at least 18 to 23 first daily dosage units of a gestagen in an
ovulation-inhibiting dose, and
(b) a second phase that consists of at least 5 to 10 second daily dosage units of a gestagen
in an ovulation-inhibiting dose, in combination with a natural estrogen.

32. A contraceptive combination which contains 28 daily dosage units with
(a) a first phase that consists of 18 to 23 first daily dosage units of a gestagen in an
ovulation-inhibiting dose, and
(b) a second phase that consists of 5 to 10 second daily dosage units of a gestagen in an
ovulation-inhibiting dose, in combination with a natural estrogen.

33. The contraceptive combination of claim 31, in which the natural estrogen is

01/24/2001 BNGUYEN1 00000021 09091665

02 FC:103
03 FC:102

90.00 OP
160.00 OP